InvestSMART

Immuron Limited (ASX: IMC) - Share Price

- Current share price for IMC : $0.040

Immuron Limited (IMC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian biopharmaceutical company engaged in the development and commercialization of orally delivered targeted polyclonal antibodies for the treatment of inflammation-related diseases and infectious diseases.

IMC General Information +

ASX Code IMC
Website http://www.immuron.com.au
Industry/Sector Biotechnology
Market Cap ($M) 12
IMC Share Price $0.040
Day High $0.000
Day Low $0.000
Last Close $0.040
IMC Share Price Movement - ( No change )
Prices as at 16:40, 30 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Immuron Limited (IMC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Immuron Limited (IMC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immuron Limited (IMC) price-sensitive announcements

IMC - Immuron FY27 Sales Update
Immuron Limited announced an unaudited FY27 first-quarter sales update for the quarter end
Immuron Limited (IMC)
27 Oct 2026 | 9:07 AM
IMC - PROIBS US Distribution Agreement
Immuron Limited announced on 4 September 2026 that it had signed an exclusive US distribut
Immuron Limited (IMC)
4 Sep 2026 | 9:24 AM
IMC - FY26 Results Presentation
Immuron Limited’s FY26 Preliminary Results Presentation highlights modest top-line growth
Immuron Limited (IMC)
28 Aug 2026 | 8:39 AM
IMC - Appendix 4E Preliminary Final Report
Immuron Limited’s Appendix 4E Preliminary Final Report for the year ended 30 June 2026 rep
Immuron Limited (IMC)
28 Aug 2026 | 8:37 AM

Immuron Limited (IMC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $13 Emerging Growth Conference Presentation 28 Oct 2026 4:11PM $0.032 $0.040 risen by 25%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $13 Immuron Updates At-The-Market Funding Facility 27 Oct 2026 1:06PM $0.036 $0.040 risen by 11.11%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $13 Immuron FY27 Sales Update 27 Oct 2026 9:07AM $0.040 $0.040 fallen by 0%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $13 CEO to present at Emerging Growth Conference 22 Oct 2026 9:09AM $0.040 $0.040 fallen by 0%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $13 Notice of Annual General Meeting and Proxy Form 16 Oct 2026 9:26AM $0.036 $0.040 risen by 11.11%
Immuron Limited (IMC)
ORDINARY FULLY PAID
 Health Care $13 Travelan Phase 2 Study Results Published 13 Oct 2026 9:15AM $0.042 $0.040 fallen by 4.76%

IMC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$3.68 -$1.20 -45.10% 0.00 0.00 0.00% 0.0%
2025A -$5.22 -$2.30 -10.70% 0.00 0.00 0.00% 0.0%
2024A -$5.77 -$2.50 52.40% 0.00 0.00 0.00% 0.0%

IMC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $94,777M 0.7309 -0.4390 0.0602 12.2355 21.8099 20.5718 2.15% 2.16% 2.23%
Immuron Limited (IMC) $13M -0.4513 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $3,019M -0.4501 0.0000 0.0000 0.0000 0.0000 1,054.5455 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,904M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,588M -1.3893 0.0000 -0.5235 0.0000 158.5882 332.8395 0.00% 0.00% 0.00%

IMC Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.16 0.00
Market 0.30 13.20 1.03 0.74
Sector 0.78 36.70 2.28 2.18

IMC Directors

Name Position Start Date
Mr Daniel Pollock Non-Executive Director 11 Oct 2012
Mr Ravi Savarirayan Non-Executive Director 7 Apr 2017
Dr Jeannie(Jeannette) Joughin Non-Executive Director 1 Jun 2024
Mr Paul Brennan Non-Executive Director, Non-Executive Chairman 16 Mar 2022

Immuron Limited (IMC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
12 Mar 2024 POLLOCK, Daniel Buy Direct Shares 200,000 $0.120 $24,000.000
12 Mar 2024 POLLOCK, Daniel Exercise Options 200,000 $0.120 $24,000.000
8 Mar 2024 POLLOCK, Daniel Sell Direct Shares 200,000 $0.157 $31,400.000

See all changes in directors' interest & trades for Immuron Limited (IMC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMC Management

Name Position
Jerry Kanellos Chief Scientific Officer
Flavio Palumbo Chief Commercial Officer
Steven Lydeamore Chief Executive Officer
Olga Smejkalova Company Secretary

IMC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immuron Limited (IMC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
113,417,824 (42.29%) HSBC Custody Nominees (Australia) Limited

IMC Calendar of Events

Date Event
23 September 2027 Report (Annual)
27 August 2027 Report (Prelim)
24 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.